Colorectal Cancer Clinical Trials

**Epidemiologic/Correlative**

**UCI 14-25**  
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

**UCI 14-36**  
A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay (Nelson)

**UCI 16-01**  
Pathway Analysis for Individualized Network Therapeutic for Cancer (PAINT) (Nelson)

**UCI 16-43**  
Prospective Collection of Human Colon Cancer Tissue Samples for Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers (Lyou)

**UCI 15-20**  
A Pilot Study to Establish Proof-of-Concept that Patient-Specific Tumor Tissue can be Maintained in the Novel Tumor-on-a-Chip Model (Zell)

**UCI 12-40**  
Atlas Colorectal Health Network (Park)

**UCI 14-30**  
Low Residue Diet vs. Clear Liquid Diet w/ Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy (Samarasena)

**UCI 14-39** **SUSPENDED**  
Phase I/Ib, Two-Part, Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study of DS-6051B, An Oral ROS1 And NTRK Inhibitor, In Subjects With Advanced Solid Tumors (Ou)

**UCI 15-74**  
Phase II Entrectinib Tx Patients with Locally Advanced/Metastatic Solid Tumors Harbor NTRK1/2/3, ROS1, ALK Gene (Seery)

**UCI 16-96**  
Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

**UCI 17-50**  
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)

**Therapeutic - Multi-site (including colon)**

**Opening Soon**

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu
Colorectal Cancer Therapeutic Clinical Trials

Stage IIA/IIIA (T2N1, T3N0, T3N1)

SWOG N1048 Phase II/III Trial of Neoadjuvant FOLFOX w/ Selective Use of Combined Modality Chemoradiation VS Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal CA Pts Undergoing LAR W/Total Mesorectal Excision (Pigazzi)

Stage 0-III

SWOG S0820 Phase IIA Randomized Double Blind Placebo-Controlled Trial of Efornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer (Zell)

Post-Adjuvant

COLORECTAL CANCER

Stage IV

UCI 15-96 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (Zell)

1st Line

UCI 17-28** Immediate Adjuvant Chemotherapy for Invasive Colonic Adenocarcinoma (Pigazzi)

2nd Line

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Seery)

** opening soon

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu